{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"915","value":"1280"},{"groupId":"OG001","value":"2020"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1410","value":"2410"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Day 7"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC).","dispersionType":"Standard Deviation","groups":[{"description":"ASTX660 120mg was orally administered once a day for 7 consecutive days every other week of each 28-day cycle (ie, \\[7 days on/ 7 days off\\] ×2; daily dosing on Days 1-7 and 15-21).","id":"OG000","title":"Cohort 1"},{"description":"ASTX660 150mg was orally administered once a day for 7 consecutive days every other week of each 28-day cycle (ie, \\[7 days on/ 7 days off\\] ×2; daily dosing on Days 1-7 and 15-21).","id":"OG001","title":"Cohort 2"}],"paramType":"MEAN","populationDescription":"PK analysis population included subjects who received at least 1 dose of IMP and had available ASTX660 concentration measurement data for at least 1 time point.","reportingStatus":"POSTED","timeFrame":"Day1: pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 24hours post-dose, Day7: pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 24, 48, 72 hours post-dose","title":"Pharmacokinetic Outcome of Concentration-time Curve (AUC)","type":"SECONDARY","unitOfMeasure":"ng∙h/mL"}